Morgan Stanley Medi Wound Ltd. Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.35 - $9.8 $4,320 - $31,360	-3,200 Reduced 10.45%	27,429 $38,000
Q2 2022 Oct 27, 2022	SELL	$1.33 - $2.35 $7,139 - $12,614	-5,368 Reduced 14.91%	30,629 $56,000
Q2 2022 Aug 15, 2022	SELL	$1.33 - $2.35 $7,139 - $12,614	-5,368 Reduced 14.91%	30,629 $56,000
Q1 2022 Oct 27, 2022	BUY	$1.86 - $3.24 $9,984 - $17,392	5,368 Added 17.53%	35,997 $72,000
Q1 2022 May 13, 2022	SELL	$1.86 - $3.24 $52,154 - $90,849	-28,040 Reduced 43.79%	35,997 $72,000
Q4 2021 Feb 14, 2022	SELL	$2.2 - $4.01 $48,202 - $87,859	-21,910 Reduced 25.49%	64,037 $152,000
Q3 2021 Nov 15, 2021	BUY	$3.34 - $4.63 $287,062 - $397,934	85,947 New	85,947 $287,000

Ticker MDWD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,735,200
Market Cap $686M
Description
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hosp...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.